{
    "name": "levocarnitine",
    "comment": "Rx",
    "other_names": [
        "Carnitor",
        "carnitine"
    ],
    "classes": [
        "Metabolic & Endocrine",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/carnitor-carnitine-levocarnitine-344516",
    "pregnancy": {
        "common": [
            "There are no adequate and well controlled studies in pregnant women."
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Reproductive studies have been performed in rats and rabbits at doses up to 3.8 times the human dose on basis of surface area and have revealed no evidence of impaired fertility or harm to the fetus; because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Supplementation in nursing mothers has not been specifically studied; studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine",
            "In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against benefits of drug supplementation to the mother; consideration may be given to discontinuation of nursing or of levocarnitine treatment."
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None listed by the manufacturer"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Monitor blood chemistries, plasma carnitine concentration, vital signs",
                "INR may increase in patients receiving warfarin therapy; monitor INR levels following initiation of levocarnitine therapy and after dose adjustments",
                "GI reactions may occur from too rapid consumption of carnitine",
                "Carcinogenic potential unknown",
                "Serious hypersensitivity reactions, including rash, urticarial, and facial edema reported; serious reactions, including anaphylaxis, laryngeal edema, and bronchospasm reported following intravenous administration, mostly in patients with end-stage renal disease undergoing dialysis; discontinue use and instruct patients to seek medical attention if they experience symptoms suggestive of a hypersensitivity reaction; "
            ],
            "specific": [
                {
                    "type": "Oral administration",
                    "description": [
                        "Gastrointestinal reactions may result from a too rapid consumption of carnitine; oral Solution and sugar-free; oral solution may be consumed alone, or dissolved in drinks or other liquid foods to reduce taste fatigue; they should be consumed slowly and doses should be spaced evenly throughout the day to maximize tolerance",
                        "The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "zavegepant intranasal",
            "description": {
                "common": "levocarnitine will increase the level or effect of zavegepant intranasal by  Other (see comment). Avoid or Use Alternate Drug. NTCP inhibitors may result in a significant increase in systemic exposure of zavegepant (a NTCP substrate)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "levocarnitine increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clonazepam",
            "description": {
                "common": "clonazepam decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "ethosuximide decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felbamate",
            "description": {
                "common": "felbamate decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gabapentin",
            "description": {
                "common": "gabapentin decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gabapentin enacarbil",
            "description": {
                "common": "gabapentin enacarbil decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lacosamide",
            "description": {
                "common": "lacosamide decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lamotrigine",
            "description": {
                "common": "lamotrigine decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levetiracetam",
            "description": {
                "common": "levetiracetam decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lorazepam",
            "description": {
                "common": "lorazepam decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methsuximide",
            "description": {
                "common": "methsuximide decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rose hips",
            "description": {
                "common": "rose hips decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rufinamide",
            "description": {
                "common": "rufinamide decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tiagabine",
            "description": {
                "common": "tiagabine decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "valproic acid",
            "description": {
                "common": "valproic acid decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zonisamide",
            "description": {
                "common": "zonisamide decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "GI distress",
            "percent": null
        },
        {
            "name": "Mild myasthenia in patients with uremia",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Hypercalcemia",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Palpitation",
            "percent": null
        },
        {
            "name": "Peripheral edema",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Bronchitis",
            "percent": null
        },
        {
            "name": "Gastritis",
            "percent": null
        },
        {
            "name": "Gastrointestinal reactions",
            "percent": null
        },
        {
            "name": "Nausea and vomiting",
            "percent": null
        },
        {
            "name": "abdominal cramps",
            "percent": null
        },
        {
            "name": "and diarrhea",
            "percent": null
        },
        {
            "name": "Musculoskeletal reactions",
            "percent": null
        },
        {
            "name": "Mild myasthenia",
            "percent": null
        },
        {
            "name": "only in uremic patients",
            "percent": null
        },
        {
            "name": "Neurologic reactions",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "and facial edema",
            "percent": null
        }
    ]
}